Relapsed and refractory aggressive NHL: Time for a change

被引：15
|
作者：
Gangatharan, Shane [1 ]
Kuruvilla, John [1 ,2 ]
机构：
[1] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
来源：
TRANSFUSION AND APHERESIS SCIENCE | 2013年 / 49卷 / 01期
关键词：
B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; PHASE-II TRIAL; HUMANIZED ANTI-CD22 ANTIBODY; PERIPHERAL T-CELL; AUTOLOGOUS TRANSPLANTATION; CONDITIONING REGIMENS; SALVAGE CHEMOTHERAPY; BRENTUXIMAB VEDOTIN; NONGERMINAL CENTER;
D O I：
10.1016/j.transci.2013.05.029
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Despite improvements in treatment for aggressive non-Hodgkin lymphoma (NHL), the outcomes for patients with relapsed or refractory B- or T-cell NHL after primary therapy remain poor. While some patients may be cured by the standard of care of salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), this treatment is unsuitable for the majority. Advances in disease biology and novel therapies have created uncertainty as to the role of old standards and opportunities to develop new rationally developed treatment options. We will review the standard approaches in this disease area and highlight areas that merit further study. (C) 2013 Published by Elsevier Ltd.
引用
收藏
页码：72 / 79
页数：8
相关论文
共 50 条
  • [21] IMPORTANCE OF MAINTAINING THE RDI OF BENDAMUSTINE COMBINED WITH RITUXIMAB WITH RELAPSED OR REFRACTORY INDOLENT NHL
    Miyazawa, Kenji
    Nakamura, Ayumi
    Kojima, Yuki
    Miyata, Yasuhiko
    Nagai, Hirokazu
    Iida, Hiroatsu
    Matsumoto, Shuichi
    ANNALS OF ONCOLOGY, 2014, 25
  • [22] VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
    Davids, M. S.
    Roberts, A. W.
    Seymour, J. F.
    Wierda, W. G.
    Puvvada, S. D.
    Gressick, L.
    Alter, D.
    Zhou, L.
    Kim, S. Y.
    Verdugo, M.
    Gerecitano, J. F.
    HAEMATOLOGICA, 2017, 102 : 218 - 219
  • [23] Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
    Davids, Matthew Steven
    Roberts, Andrew Warwick
    Seymour, John Francis
    Wierda, William G.
    Puvvada, Soham D.
    Gressick, Lori A.
    Alter, Debbie
    Zhou, Lang
    Kim, Su Young
    Verdugo, Maria
    Gerecitano, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Study of serum vascular endothelial growth factor and serum basic fibroblast growth factor in relapsed and refractory aggressive NHL and response to ICE protocol
    Abu-Taleb, F
    Amin, I
    Esh, S
    Mohamed, A
    ANNALS OF ONCOLOGY, 2005, 16 : 180 - 180
  • [25] Are two monoclonal antibodies more effective than a single in the relapsed or refractory NHL?
    Choquet, Sylvain
    HEMATOLOGIE, 2005, 11 (05): : 302 - 302
  • [26] Venetoclax (VEN) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).
    Davids, M.
    Roberts, A.
    Seymour, J.
    Wierda, W.
    Puvvada, S.
    Gressick, L.
    Alter, D.
    Zhou, L.
    Kim, S.
    Verdugo, M.
    Gerecitano, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 74 - 74
  • [27] Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis
    Parekh, Deevyashali
    Lin, Howard
    Batajoo, Akanksha
    Peckham-Gregory, Erin
    Karri, Vivekanudeep
    Stanton, Whitney
    Scull, Brooks
    Fleishmann, Ryan
    El-Mallawany, Nader
    Eckstein, Olive S.
    Prudowsky, Zachary D.
    Gulati, Nitya
    Agrusa, Jennifer E.
    Ahmed, Asra Z.
    Chu, Roland
    Dietz, Matthew S.
    Goldman, Stanton C.
    Hogarty, Michael D.
    Imran, Hamayun
    Intzes, Stefanos
    Kim, Jenny M.
    Kopp, Lisa M.
    Levy, Carolyn Fein
    Neff, Philip
    Pillai, Pallavi M.
    Sisk, Bryan A.
    Schiff, Deborah E.
    Trobaugh-Lotrario, Angela D.
    Walkovich, Kelly
    McClain, Kenneth L.
    Allen, Carl E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (05) : 1888 - 1893
  • [28] Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL)
    Evens, Andrew M.
    Gordon, Leo I.
    Patton, David
    Rosen, Steven T.
    Winter, Jane N.
    Kline, Justin
    Van Besien, Koen
    Smith, Sonali M.
    BLOOD, 2008, 112 (11) : 700 - 700
  • [29] Stem Cell Dose and Time To Engraftment Does Not Predict Outcome After Autologous Stem Cell Transplantation For Relapsed Aggressive NHL
    Gangatharan, Shane A.
    Kuruvilla, John
    Kukreti, Vishal
    Keating, Armand
    Maganti, Manjula
    Pintilie, Melania
    Crump, Michael
    BLOOD, 2013, 122 (21)
  • [30] Chemoimmunotherapy in aggressive NHL
    Pfreundschuh, Michael
    ANNALS OF ONCOLOGY, 2006, 17 : 46 - 46
12345